Last reviewed · How we verify
placebo to fexofenadine
placebo to fexofenadine is a Small molecule drug developed by Bayer. It is currently FDA-approved for Control arm in clinical trials comparing fexofenadine efficacy.
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials. Used for Control arm in clinical trials comparing fexofenadine efficacy.
At a glance
| Generic name | placebo to fexofenadine |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Placebo is a non-therapeutic control agent administered in blinded studies to establish baseline efficacy and safety profiles against which active drugs are compared. Any observed effects are attributable to the placebo effect—psychological and contextual factors rather than direct molecular action. In this context, placebo serves as the comparator arm against fexofenadine, a selective H1-receptor antagonist.
Approved indications
- Control arm in clinical trials comparing fexofenadine efficacy
Common side effects
- Placebo effect (symptom improvement unrelated to active drug)
Key clinical trials
- A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol (PHASE1, PHASE2)
- Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) (PHASE3)
- Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment (PHASE3)
- A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis (PHASE3)
- Fexofenadine in Patients With Active Rheumatoid Arthritis (PHASE1, PHASE2)
- Effect of Antihistamines on Ureteral Stent-Related Symptoms (PHASE2)
- Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers (PHASE1)
- Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo to fexofenadine CI brief — competitive landscape report
- placebo to fexofenadine updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about placebo to fexofenadine
What is placebo to fexofenadine?
How does placebo to fexofenadine work?
What is placebo to fexofenadine used for?
Who makes placebo to fexofenadine?
What development phase is placebo to fexofenadine in?
What are the side effects of placebo to fexofenadine?
Related
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Allergy/Immunology
- Indication: Drugs for Control arm in clinical trials comparing fexofenadine efficacy
- Compare: placebo to fexofenadine vs similar drugs
- Pricing: placebo to fexofenadine cost, discount & access